193 related articles for article (PubMed ID: 12869639)
1. Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive element.
Miao W; Hu L; Kandouz M; Batist G
Mol Pharmacol; 2003 Aug; 64(2):346-54. PubMed ID: 12869639
[TBL] [Abstract][Full Text] [Related]
2. Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells.
O'Dwyer PJ; Clayton M; Halbherr T; Myers CB; Yao Ks
Clin Cancer Res; 1997 May; 3(5):783-91. PubMed ID: 9815750
[TBL] [Abstract][Full Text] [Related]
3. Oltipraz inhibits 3-methylcholanthrene induction of CYP1A1 by CCAAT/enhancer-binding protein activation.
Cho IJ; Kim SG
J Biol Chem; 2003 Nov; 278(45):44103-12. PubMed ID: 12941938
[TBL] [Abstract][Full Text] [Related]
4. Role of hepatitis B virus X repression of C/EBPbeta activity in the down-regulation of glutathione S-transferase A2 gene: implications in other phase II detoxifying enzyme expression.
Cho IJ; Ki SH; Brooks C; Kim SG
Xenobiotica; 2009 Feb; 39(2):182-92. PubMed ID: 19255944
[TBL] [Abstract][Full Text] [Related]
5. Cell-based studies reveal differences in glutathione S-transferase induction between oltipraz and tert-butylhydroquinone.
Lamb JG; Franklin MR
J Biochem Mol Toxicol; 2002; 16(4):154-61. PubMed ID: 12242683
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of the oxidized metabolites of oltipraz on the activation of CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 for GSTA2 gene induction.
Ko MS; Lee SJ; Kim JW; Lim JW; Kim SG
Drug Metab Dispos; 2006 Aug; 34(8):1353-60. PubMed ID: 16714377
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of rat UDP-glucuronosyltransferase 1A6 induction by oltipraz: evidence for a contribution of the Aryl hydrocarbon receptor pathway.
Auyeung DJ; Kessler FK; Ritter JK
Mol Pharmacol; 2003 Jan; 63(1):119-27. PubMed ID: 12488544
[TBL] [Abstract][Full Text] [Related]
8. Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2.
Köhle C; Bock KW
Biochem Pharmacol; 2007 Jun; 73(12):1853-62. PubMed ID: 17266942
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz.
Roebuck BD; Curphey TJ; Li Y; Baumgartner KJ; Bodreddigari S; Yan J; Gange SJ; Kensler TW; Sutter TR
Carcinogenesis; 2003 Dec; 24(12):1919-28. PubMed ID: 14555609
[TBL] [Abstract][Full Text] [Related]
10. Suppression of CYP1A1 transcription by H2O2 is mediated by xenobiotic-response element.
Xu C; Pasco DS
Arch Biochem Biophys; 1998 Aug; 356(2):142-50. PubMed ID: 9705204
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent.
Le Ferrec E; Lagadic-Gossmann D; Rauch C; Bardiau C; Maheo K; Massiere F; Le Vee M; Guillouzo A; Morel F
J Biol Chem; 2002 Jul; 277(27):24780-7. PubMed ID: 11959854
[TBL] [Abstract][Full Text] [Related]
12. Phase II-selective induction of hepatic drug-metabolizing enzymes by oltipraz -5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione-, 1,7-phenanthroline, and 2,2'-dipyridyl in rats is not accompanied by induction of intestinal enzymes.
Vargas M; Lamb JG; Franklin MR
Drug Metab Dispos; 1998 Feb; 26(2):91-7. PubMed ID: 9456293
[TBL] [Abstract][Full Text] [Related]
13. Genotoxic polycyclic aromatic hydrocarbon ortho-quinones generated by aldo-keto reductases induce CYP1A1 via nuclear translocation of the aryl hydrocarbon receptor.
Burczynski ME; Penning TM
Cancer Res; 2000 Feb; 60(4):908-15. PubMed ID: 10706104
[TBL] [Abstract][Full Text] [Related]
14. Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz.
Buetler TM; Gallagher EP; Wang C; Stahl DL; Hayes JD; Eaton DL
Toxicol Appl Pharmacol; 1995 Nov; 135(1):45-57. PubMed ID: 7482539
[TBL] [Abstract][Full Text] [Related]
15. Coordinate induction of glutathione S-transferase alpha, mu, and pi expression in murine liver after a single administration of oltipraz.
Clapper ML; Everley LC; Strobel LA; Townsend AJ; Engstrom PF
Mol Pharmacol; 1994 Mar; 45(3):469-74. PubMed ID: 7511779
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes.
Miao W; Hu L; Scrivens PJ; Batist G
J Biol Chem; 2005 May; 280(21):20340-8. PubMed ID: 15790560
[TBL] [Abstract][Full Text] [Related]
17. Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-beta for GSTA2 gene transactivation.
Lee SJ; Kim SG
Mol Pharmacol; 2006 Jan; 69(1):385-96. PubMed ID: 16246908
[TBL] [Abstract][Full Text] [Related]
18. A cell-based system to identify and characterize the molecular mechanism of drug-metabolizing enzyme (DME) modulators.
Miao W; Hu L; Kandouz M; Hamilton D; Batist G
Biochem Pharmacol; 2004 May; 67(10):1897-905. PubMed ID: 15130766
[TBL] [Abstract][Full Text] [Related]
19. Shifted concentration dependency of EpRE- and XRE-mediated gene expression points at monofunctional EpRE-mediated induction by flavonoids at physiologically relevant concentrations.
Lee-Hilz YY; ter Borg S; van Berkel WJ; Rietjens IM; Aarts JM
Toxicol In Vitro; 2008 Jun; 22(4):921-6. PubMed ID: 18314304
[TBL] [Abstract][Full Text] [Related]
20. Protection of retinal pigment epithelial cells from oxidative damage by oltipraz, a cancer chemopreventive agent.
Nelson KC; Armstrong JS; Moriarty S; Cai J; Wu MW; Sternberg P; Jones DP
Invest Ophthalmol Vis Sci; 2002 Nov; 43(11):3550-4. PubMed ID: 12407167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
